Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on COLL. Truist Financial set a $55.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Barclays initiated coverage on Collegium Pharmaceutical in a research note on Monday, December 8th. They issued an “overweight” rating and a $58.00 price objective on the stock. HC Wainwright increased their target price on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.40.

Collegium Pharmaceutical Trading Up 2.3%

Shares of COLL opened at $47.26 on Tuesday. The stock’s 50-day moving average price is $45.77 and its 200 day moving average price is $38.30. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $50.79. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 29.35 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business had revenue of $135.55 million for the quarter. As a group, research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director owned 52,629 shares in the company, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 51,250 shares of company stock worth $2,235,352 in the last 90 days. Corporate insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC grew its position in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the period. Two Sigma Investments LP grew its position in shares of Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after purchasing an additional 242,310 shares during the period. Qube Research & Technologies Ltd increased its position in shares of Collegium Pharmaceutical by 237.9% during the third quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after acquiring an additional 225,679 shares in the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Collegium Pharmaceutical by 854.2% during the third quarter. Voloridge Investment Management LLC now owns 249,473 shares of the specialty pharmaceutical company’s stock worth $8,729,000 after acquiring an additional 223,329 shares during the period. Finally, Amundi bought a new stake in Collegium Pharmaceutical in the 3rd quarter valued at $6,276,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.